(Q40488107)

21 September 2017

title

Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer (English)

1 reference

21 September 2017

1 reference

Sang-Jin Lee

1

1 reference

21 September 2017

Yanping Zhang

2

1 reference

21 September 2017

Sang Don Lee

3

1 reference

21 September 2017

Chaeyong Jung

4

1 reference

21 September 2017

Xiong Li

5

1 reference

21 September 2017

Hong-Sup Kim

6

1 reference

21 September 2017

Kyung-Hee Bae

7

1 reference

21 September 2017

Meei-Huey Jeng

8

1 reference

21 September 2017

Chinghai Kao

9

1 reference

21 September 2017

Thomas Gardner

10

1 reference

21 September 2017

publication date

1 December 2004

1 reference

21 September 2017

1 reference

21 September 2017

volume

10

1 reference

21 September 2017

issue

6

1 reference

21 September 2017

page(s)

1051-1058

1 reference

21 September 2017

cites work

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.08.028

Tumour suppressor genes in prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.08.028

Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.08.028

The development of androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.08.028

Carcinoma of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.08.028

In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: a potential alternative approach to androgen deprivation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.08.028

Ad5CMVp53 gene therapy for locally advanced prostate cancer--where do we stand?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.08.028

Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.08.028

Adenovirus-mediated interferon-beta gene therapy suppresses growth and metastasis of human prostate cancer in nude mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.08.028

Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.08.028

Replicating viruses as selective cancer therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.08.028

Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.08.028

Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.08.028

A tissue-specific enhancer of the prostate-specific membrane antigen gene, FOLH1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.08.028

Novel prostate-specific promoter derived from PSA and PSMA enhancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.08.028

Replicative adenoviruses for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.08.028

Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.08.028

NFATc1 with AP-3 site binding specificity mediates gene expression of prostate-specific-membrane-antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.08.028

Telomerase-dependent oncolytic adenovirus for cancer treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.08.028

Characterization of the role of IL-6 in the progression of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.08.028

Molecular determinants of resistance to antiandrogen therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.08.028

In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.08.028

Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.08.028

PSMA specific antibodies and their diagnostic and therapeutic use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.08.028

In vitro propagated dendritic cells from prostate cancer patients as a component of prostate cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.08.028

Effect of castration and sex hormone treatment on survival, anti-nucleic acid antibodies, and glomerulonephritis in NZB/NZW F1 mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.08.028

10.1016/J.YMTHE.2004.08.028

7 January 2021

Identifiers

DOI

1 reference

release_gtovou75ynbf7osfzn43exr5ai

21 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/gtovou75ynbf7osfzn43exr5ai

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference